Home » Business News » 2013 » April » April 26, 2013

Vicente Anido, Jr. nominated for election to Nicox's Board of Directors

April 26, 2013 - Sophia Antipolis Cedex, France

Nicox S.A. (NYSE EuronextParis: COX) today announced that the Company's Boardof Directors has nominated Vicente Anido, Jr., PhD., to be elected to theBoard. Dr. Anido is a highly respected and experienced leader in theophthalmologysector. He most recently served as President and Chief Executive Officer ofISTAPharmaceuticals prior to its acquisition by Bausch + Lomb. The election ofDr.Anido to Nicox's Board will be voted on at the Company's 2013 OrdinaryShareholder Meeting, which will be convened for June 6, 2013.

"The Board is pleased to propose Vince Anido as a Board member of Nicox.Vincehas a wealth of experience in the management of pharmaceutical companies,particularly in the ophthalmic area. We believe he would be a significantaddition to the existing strength and combined experience of the NicoxBoard aswe work towards building an international ophthalmology business," saidMicheleGarufi, Chief Executive Officer of Nicox.

About Vicente Anido, Jr.

From 2001 to 2012, Dr. Anido was President, Chief Executive Officer and aDirector of ISTA Pharmaceuticals, a US-based ophthalmic pharmaceuticalcompany.Prior to this, he was general partner of Windamere Venture Partners, servedasPresident and CEO of CombiChem, Inc., a biotechnology company, and wasPresidentof the Americas Region of Allergan, a specialty pharmaceutical companyfocusingon ophthalmology, dermatology and neuromuscular indications.Dr. Anido currently serves on the Board of Directors of QLT Inc. andDepomedInc., two NASDAQ-listed pharmaceutical companies, and was recently namedChairman of the Board of Directors of Aerie Pharmaceuticals, a US privateophthalmic company.

Dr. Anido received a B.S. in Pharmacy, an M.S. in Pharmacy AdministrationfromWest Virginia University and a Ph.D. in Pharmacy Administration from theUniversity of Missouri.

Information on the 2013 Ordinary Shareholder Meeting is available on theNicox internet website:

About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is creating a new mid-sizedinternational player in the ophthalmic market by building adiversifiedportfolio of innovative therapies and diagnostic tools. With aheritage ofscientific, business development and commercial expertise, the Nicoxteam isfocused on developing and marketing novel pharmaceuticals and diagnosticdevicesthat can help people to enhance their sight. In the United States, NicoxmarketsAdenoPlus™, a test for the differential diagnosis of acuteconjunctivitis in-licensed from RPS®.

The Company's pipeline includes latanoprostene bunod, a novel drug-candidatebased on Nicox's proprietary nitric oxide (NO)-donating R&D platform,developedin collaboration with Bausch + Lomb for the potential treatment ofglaucoma andocular hypertension. Further NO-donating compounds are under development innon-ophthalmic indications, notably through partners, including Merck (knownas MSDoutside the United States and Canada) and Ferrer.

Nicox S.A. is headquartered in France and is listed on EuronextParis(Compartment B: Small Caps). For more information please

This press release contains certain forward-looking statements. AlthoughtheCompany believes its expectations are based on reasonable assumptions,theseforward-looking statements are subject to numerous risks and uncertainties,which could cause actual results to differ materially from thoseanticipated inthe forward-looking statements.

Risks factors which are likely to have a material effect on Nicox'sbusiness arepresented in the 4th chapter of the « Document de référence,rapport financierannuel et rapport de gestion 2012 » filed with the FrenchAutorité des MarchésFinanciers (AMF) on March 22, 2013 and available on Nicox's website( and on the AMF's website ( Anido, Jr. nominated for election to Nicox's Board of Director:

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: NICOX via Thomson Reuters ONE


Nicox Contacts

Gavin Spencer
Executive Vice President Corporate Development
Tel +33 (0)4 97 24 53 00
Email Contact

Media Relations
FTI Consulting

Jonathan Birt
D +44 (0)20 7269 7205
M +44 (0) 7515 597 858
Email Contact

Stephanie Cuthbert
D +44 (0)20 3077 0458
M +44 (0) 7843 080947
Email Contact

Nicox S.A.
Drakkar 2
Bat D
2405 route des Dolines
CS 10313
Sophia Antipolis
06560 Valbonne, France
T: +33 (0)4 97 24 53 00
F: +33 (0)4 97 24 53 99


Comment on this story